USE OF INACTIVATED NONREPLICATING MODIFIED VACCINIA VIRUS ANKARA (MVA) AS MONOIMMUNOTHERAPY OR IN COMBINATION WITH IMMUME CHECKPOINT BLOCKING AGENTS FOR SOLID TUMORS

• US 20180236062A1
• Filed: 02/25/2016
• Published: 08/23/2018
• Est. Priority Date: 02/25/2015
• Status: Active Grant

• Current Assignee: Memorial Sloan-Kettering Cancer Center
• Original Assignee: Memorial Sloan-Kettering Cancer Center
• Inventors: Deng, Liang, Shuman, Stewart, Wolchok, Jedd D., Merghoub, Taha, Dai, Peihong, Wang, Weiyi
• Granted Patent: US 10,639,366 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/5252 inactivated (killed)
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/285 Vaccinia virus or variola virus
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The present disclosure relates to infection-competent, but nonreplicative inactivated modified vaccinia Ankara (MVA) and its use as immunotherapy, alone, or in combination with immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to inducing an immune response in a subject diagnosed with a solid malignant tumor.

Claims

1. A method for treating a solid malignant tumor in a subject in need thereof, the method comprising delivering to cells of the tumor a therapeutically effective amount of inactivated modified vaccinia Ankara virus (inactivated-MVA), thereby resulting in the treatment of the tumor.

2. The method of claim 1, wherein the treatment comprises one or more of the following:

inducing the immune system of the subject to mount an immune response against the tumor;

reducing the size of the tumor;

eradicating the tumor;

inhibiting growth of the tumor;

inhibiting metastasis of the tumor; and

reducing or eradicating metastatic tumor

as compared to an untreated control subject.

3. The method of claim 2, wherein the tumor includes tumor located at the site of inactivated-MVA delivery, or tumor located both at the site and elsewhere in the body of the subject.

4. The method of claim 1, wherein the delivery of inactivated-MVA elicits an antitumor immune response comprising one or more of the following:

increased cytotoxic CD8+ T cells within the tumor and/or in tumor-draining lymph nodes;

induction of maturation of dendritic cells infiltrating the tumor through induction of type I IFN;

induction of activated CD4+ effector T cells in the subject recognizing tumor cells within the tumor or systemically;

reduced immune suppressive (regulatory) CD4+ T cells within the tumor; and

induction of cells of the tumor to express MHC Class I on their surface and to produce Type I IFN

as compared to an untreated control subject.

5. The method of claim 1, wherein the tumor is primary or metastatic melanoma, or primary or metastatic colon carcinoma.

8. The method of claim 1, wherein the inactivated-MVA is delivered parenterally by intratumoral or intravenous injection.

11. The method of claim 1, wherein the inactivated-MVA is delivered at a dosage per administration of about 10⁵ to about 10¹⁰ plaque-forming units (pfu).

13. The method of claim 1, wherein the delivery is repeated with a frequency within the range from once per month to once per week or more, and continues for several weeks, months, years, or indefinitely until a maximum tolerated dose is reached.

15. The method of claim 1, wherein the inactivated-MVA is heat-inactivated MVA or UV-inactivated MVA.

61. The method of claim 1, wherein the inactivated-MVA does not comprise a heterologous nucleic acid encoding or expressing a tumor antigen.

6-7. -7. (canceled)

9-10. -10. (canceled)

12. (canceled)

14. (canceled)

16-37. -37. (canceled)

38. A method for treating a solid malignant tumor in a subject in need thereof, the method comprising delivering to tumor cells of the subject a therapeutically effective amount of inactivated modified vaccinia Ankara virus (inactivated-MVA) and conjointly administering to the subject a therapeutically effective amount of an immune checkpoint blocking agent.

39. The method of claim 38, wherein the inactivated-MVA is delivered intratumorally and/or intravenously to the subject, and wherein the immune checkpoint blocking agent is administered intratumorally and/or intravenously to the subject.

43. The method of claim 38, wherein the immune checkpoint blocking agent modulates the activity of one or more checkpoint proteins selected from the group consisting of CTLA-4 or its ligands, PD-1 or its ligands, PD-L1, PD-L2, TIGIT, LAG3, B7-H3, B7-H4, TIM3, ICOS, BTLA, and CD28.

45. The method of claim 38, wherein the tumor is primary or metastatic melanoma, or primary or metastatic colon carcinoma.

46. The method of claim 38, wherein the inactivated-MVA is delivered to the subject separately, sequentially, or simultaneously with the administration of an immune checkpoint blocking agent.

49. The method of claim 38, wherein one or both of the inactivated-MVA and the immune checkpoint blocking agent are respectively delivered and administered during a period of time of several weeks, months, or years, or indefinitely until a maximum tolerated dose is reached.

50. The method of claim 38, wherein the inactivated MVA is delivered at a dosage per administration of about 10⁵ to about 10¹⁰ plaque-forming units (pfu).

54. The method of claim 38, wherein the inactivated MVA is heat-inactivated MVA or UV-inactivated MVA.

62. The method of claim 38, wherein the inactivated-MVA does not comprise a heterologous nucleic acid encoding or expressing a tumor antigen.

63. The method of claim 38, wherein the combination of the inactivated-MVA and the immune checkpoint blocking agent has a synergistic effect in the treatment of the tumor.

40-42. -42. (canceled)

44. (canceled)

47-48. -48. (canceled)

51-53. -53. (canceled)

55-60. -60. (canceled)